Navigation Links
Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference
Date:5/23/2013

CARLSBAD, Calif., May 23, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Thursday, May 30, 2013 at 8:40 a.m. ET in Boston, MA.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be conside
'/>"/>

SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
2. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
3. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
4. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
5. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
6. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
11. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... June 30, 2015. All comparisons, unless otherwise noted, are to ... Quarter 2015 Highlights include: , Revenue of $808 ... Total prescriptions dispensed of 234,000, an increase of 19% ... EBITDA of $22.7 million, an increase of 287% or $16.8 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, 2015 , ... ... for the upcoming Pop & Rock Beauty Bash Tour. In addition, they have signed ... spokesperson. Lexi’s image will appear in forthcoming print and overall branding opportunities for the ...
(Date:8/4/2015)... ... ... More than 700 years of marital bliss were celebrated as 13 couples from Friendship ... Kafader and Richard Oas lead the non-denominational service for married couples wishing to reaffirm ... by the Moonlight Serenade Orchestra and a special honeymoon dinner featuring lobster and steak. ...
(Date:8/4/2015)... ... 2015 , ... Dr. Gary Richter, Montclair Veterinary Hospital, Oakland, ... contest is put on by the American Veterinary Medical Foundation (AVMF). , Dr. ... on community involvement, ethical behavior, passion for profession, and their connections to pets ...
(Date:8/4/2015)... Dallas, Texas (PRWEB) , ... August 04, 2015 , ... ... involved in allegedly defective medical device lawsuit claims dealing with Inferior Vena Cava Filters ... been filing the firm’s federal cases for Cook IVC Filter clients under In re ...
(Date:8/4/2015)... St. Louis, MO (PRWEB) , ... August 04, ... ... news, attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report ... documents.* Talcum powder lawyers provide regular news updates and cancer warning ...
Breaking Medicine News(10 mins):Health News:Rock Your Hair Signs On As Title Sponsor For The HYPE! Projects Pop & Rock Beauty Bash Tour 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4
... Will Earn Decision Resources, Gold Standard for Rheumatoid ... from Decision ResourcesWALTHAM, Mass., Jan. 28 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... on reducing the signs and symptoms of rheumatoid ...
... Data Show Significant Reduction In Snoring Events, Increase ... 28 AirWare, Inc., maker of Brez premium ... for inside the nose clinically proven to reduce ... bed partner, today announced availability in all Rite ...
... shows that very low amounts of Micromet,s EpCAM-targeting BiTE ... 28 Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, today announced ... Immunobiology describing in detail the mode of action ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ... first fiscal quarter ended December 31, 2008, representing an increase ... quarter,s growth rate reflects the unfavorable impact from foreign currency ... percentage points. "BD is off to a solid start ...
... Inc. (Pink Sheets: PCIR) today announced it has entered ... spin off its wholly owned subsidiary, Prepaid Tel.com, Inc., ... firm which, once it has gone public, will reward ... company.The agreement with TransPacific Telecom, Inc., the developer of ...
... have delivered the world’s first commercially cloned dog, a 10-week old ... , ... Boca Raton, FL (Vocus) January 28, 2009 -- ... commercially cloned dog, a 10-week old Labrador named Lancey, to Florida ...
Cached Medicine News:Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 2Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 2Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 3Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 5Health News:BD Announces Results for First Fiscal Quarter 2Health News:BD Announces Results for First Fiscal Quarter 3Health News:BD Announces Results for First Fiscal Quarter 4Health News:BD Announces Results for First Fiscal Quarter 5Health News:BD Announces Results for First Fiscal Quarter 6Health News:BD Announces Results for First Fiscal Quarter 7Health News:BD Announces Results for First Fiscal Quarter 8Health News:BD Announces Results for First Fiscal Quarter 9Health News:BD Announces Results for First Fiscal Quarter 10Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:First Commercially Cloned Dog Delivered to Florida Family 2
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of alanine aminotransferase in serum or plasma....
Medicine Products: